NewcelX Ltd.
NCEL Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$2.74
KIRA · Stoqly’s AI analyst, in plain words
- NewcelX Ltd. lost $8.3M in fiscal 2025.
- Free cash flow was −$2.8M in fiscal 2025, — of revenue.
- NewcelX Ltd. has $1.8M more cash than debt.
Market cap
$10.5M
P/E
1.3x
Revenue
—
Net income
−$8.3M
Free cash flow
−$2.8M
Operating margin
—
NewcelX Ltd. in 30 seconds · fiscal 2025
Does it make a profit?
−$8.3M
No. It lost money last year.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
1.3x
One share costs 1.3 times its yearly profit per share.
What NewcelX Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 29, 2026
- Legal name
- NewcelX Ltd.
- CIK
- 0001783036
NewcelX Ltd. · NCEL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$11.9M | −$16.5M | −$3.3M | −$7.2M | −$8.3M |
| Diluted EPS | −$1.00 | −$33.52 | $1.13 | $2.43 | $2.16 |
| Cash | |||||
| Cash from operations | −$14.9M | −$13.9M | −$3.4M | −$1.1M | −$2.8M |
| Capital expenditure | $0.0M | — | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$15.0M | — | −$3.5M | −$1.1M | −$2.8M |
| Share count change | 71.0% | −95.9% | 500.5% | 0.1% | 29.9% |
| Debt and strength | |||||
| Cash and short-term investments | $5.4M | $8.9M | $1.1M | $0.7M | $2.2M |
| Debt incl. finance leases | — | — | — | $7.7M | $0.4M |
| Shareholders' equity | $0.5M | $0.1M | −$1.2M | −$8.0M | $7.3M |
| Current ratio | 2.4x | 2.8x | 0.2x | 0.1x | 0.8x |
| Interest coverage | −246.6x | −162.6x | −25.1x | −45.8x | — |
| Returns and quality | |||||
| Return on capital | — | — | — | — | −37.5% |
| Return on equity | — | −5,049.2% | — | — | — |
| Return on tangible equity | −2,202.5% | −14,861.0% | — | — | 150.4% |
| Piotroski F-score | — | — | — | — | 4 |
| Altman Z'' | −33.5 | −27.5 | −157.0 | −351.8 | −24.5 |
Insiders bought, 12 months
$0.4M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
NewcelX Ltd. · NCEL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.74 a share, the company is worth $10.5M: 1.3 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001783036). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.